INS and metabolic dysfunction-associated steatohepatitis: NASH is usually characterized by IR as a main contributor to its pathophysiology and several pharmacological options have been used for its management such as insulin sensitizers and lipid-lowering agents, and both exerted weak effects or long-term side effects that prohibited their use (Gerges et al. 2020, Godoy-Matos et al. 2020).